Zuranolone

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 172 publications

Zuranolone mitigates delirium-like bispectral EEG changes, behavioral deficits, and neuroinflammation across surgical and inflammatory mouse models and age groups.

Zuranolone mitigates delirium-like bispectral EEG changes, behavioral deficits, and neuroinflammation across surgical and inflammatory mouse models and age groups.

Journal: bioRxiv : the preprint server for biology

Published: June 04, 2026

Real-world adverse event profiles of Zuranolone and Brexanolone based on FAERS and VigiAccess databases: An observational study.

Real-world adverse event profiles of Zuranolone and Brexanolone based on FAERS and VigiAccess databases: An observational study.

Journal: Medicine

Published: June 01, 2026

First Reported Case of Dissociative Symptoms Associated With Zuranolone Use in Peripartum Depression.

First Reported Case of Dissociative Symptoms Associated With Zuranolone Use in Peripartum Depression.

Journal: Cureus

Published: May 28, 2026

Pharmacotherapeutic approaches to treating postpartum depression: a focus on GABAA receptor positive allosteric modulators.

Pharmacotherapeutic approaches to treating postpartum depression: a focus on GABAA receptor positive allosteric modulators.

Journal: Expert opinion on pharmacotherapy

Published: May 18, 2026

Updated guidelines for pharmacologic treatment of perinatal depression: Understanding medication options.

Updated guidelines for pharmacologic treatment of perinatal depression: Understanding medication options.

Journal: Cleveland Clinic journal of medicine

Published: April 01, 2026

Comparative efficacy and acceptability of pharmacological interventions for postpartum depression: a systematic review and network meta-analysis.

Comparative efficacy and acceptability of pharmacological interventions for postpartum depression: a systematic review and network meta-analysis.

Journal: Psychiatry research

Published: March 25, 2026

Next-Generation Pharmacotherapy for Depressive Disorders: From Novel Compounds to Optimized Use of Available Drugs.

Next-Generation Pharmacotherapy for Depressive Disorders: From Novel Compounds to Optimized Use of Available Drugs.

Journal: Drug design, development and therapy

Published: March 24, 2026

ACOG Clinical Practice Update, Zuranolone and Brexanolone for the Treatment of Postpartum Depression: Correction.

ACOG Clinical Practice Update, Zuranolone and Brexanolone for the Treatment of Postpartum Depression: Correction.

Journal: Obstetrics and gynecology

Published: March 19, 2026

Examining New Mothers' Access to Zuranolone.

Examining New Mothers' Access to Zuranolone.

Journal: Ochsner journal

Published: March 19, 2026

▼Zuranolone for the treatment of moderate or severe postnatal depression.

▼Zuranolone for the treatment of moderate or severe postnatal depression.

Journal: Drug and therapeutics bulletin

Published: March 04, 2026

Global perspectives on central nervous system drug innovation: achievements, barriers, and priorities for the next decade.

Global perspectives on central nervous system drug innovation: achievements, barriers, and priorities for the next decade.

Journal: The international journal of neuropsychopharmacology

Published: February 12, 2026

Response to Durability of zuranolone in postpartum depression versus major depressive disorder.

Response to Durability of zuranolone in postpartum depression versus major depressive disorder.

Journal: Psychiatry and clinical neurosciences

Published: February 09, 2026

Showing 1-12 of 172

Last Updated: 09/26/2026